Hepatitis B Immunisation: A Two-part Study Investigating Antigen Specific B Cell Receptors
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Hepatitis B vaccine recombinant (HBvaxPro) (Primary) ; Hepatitis B vaccine
- Indications Hepatitis B
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- 23 Oct 2013 Accrual to date is 93% according to United Kingdom Clinical Research Network.
- 12 Sep 2013 Accrual to date is 68% according to United Kingdom Clinical Research Network.
- 01 Aug 2013 Planned end date changed from 1 Aug 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.